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Abstract
Background
Prior studies evaluating the impact of hysteroscopy on outcomes in endometrial cancer
have predominantly evaluated type I tumors. We sought to evaluate whether hysteroscopy
worsens prognosis in type II endometrial cancer.
Methods
A retrospective cohort analysis of 140 patients from two institutions with type II endometrial
cancer was performed. Women who underwent either diagnostic hysteroscopy (HSC) or
dilation and curettage (D&C) for cancer diagnosis from June 2001 until June 2010 were
included. The clinical and pathologic characteristics, including peritoneal cytology results
were reviewed. The primary endpoint was disease-specific survival (DSS). The exposure of
interest was hysteroscopy. Survival curves were projected using the Kaplan-Meier method
and compared using the log-rank test.
Results
There was no difference in age, histology, stage, depth of myometrial invasion, adnexal
involvement, or nodal metastasis between HSC and D&C patients. Positive cytology was
found in 16/54 (30%) patients following HSC and in 10/86 (12%) following D&C (p = 0.008).
Fourteen patients with stage I and II disease had positive peritoneal cytology, with 11/40
(27.5%) patients in the HSC group and 3/59 (5%) patients in the D&C group(p = 0.002).
Median DSS was clinically different for the HSC and D&C groups, but statistical significance
was not reached (53 versus 63.5 months, p = 0.34). For stage I and II patients, 18/99 (18%)
were dead of EC, with a median DSS of 60 months for HSC and 71 months for D&C (p =
0.82). Overall 46 (33%) patients developed a recurrence, with 18/54 (33%) in the HSC
group compared to 28/86 (32%) in the D&C group (p = 0.92). There was no difference in
recurrence location between groups.
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Conclusions
Diagnostic hysteroscopy significantly increased the rate of positive peritoneal cytology at
the time of surgical staging in this cohort of patients with type II EC. However, we were
unable to detect a difference in prognosis as measured by DSS.
Introduction
Endometrial cancer (EC) is the most common malignancy of the female genital system, and
can be classified into type I and type II tumors[1]. Type I tumors are of endometrioid histology
and are the most common type of EC. These tumors are associated with estrogen dependence
and favorable prognosis [2–4]. Type II tumors include a variety of histologies such as serous
and clear cell carcinomas. These tumors are associated with poor clinical outcomes [3–5].
More recently, carcinosarcoma has also been included in type II tumors as it is considered a
metaplastic carcinoma by the 2010 National Comprehensive Cancer Network (NCCN) panel
[6]. Compared with type I EC, type II EC behaves more aggressively with a higher incidence of
extrauterine disease and increased propensity for recurrence[7,8]. The 5-year survival rate for
type II EC is reported to be between 30% and 60% [9–11].
Hysteroscopy (HSC) is a procedure that is often used to assist in the diagnosis of EC. The
accuracy of hysteroscopically-guided curettage was shown to be higher than D&C alone in a
meta-analysis and is preferred by some providers [11]. However, due to the use of distention
media and increased intrauterine pressure, there is a theoretical concern that HSC may facili-
tate the dissemination of malignant cells into peritoneal cavity though the fallopian tubes.
Most retrospective studies have found that despite the higher prevalence of positive peritoneal
cytology following HSC, there is no evidence to suggest that HSC is associated with increased
mortality or worsened prognosis in women with EC [12–17]. However, to date, all studies eval-
uating the risk of HSC in EC prognosis have predominantly included patients with type I EC.
With no studies specifically addressing type II EC, the effect of peritoneal dissemination of
malignant cells in this subset of EC remains less clear. We hypothesized that peritoneal dissem-
ination of malignant cells following HSC in type II EC, due to its more aggressive nature,
would negatively impact the prognosis of these patients. Thus, we conducted a retrospective
cohort study among patients with type II EC to evaluate the effect of HSC on survival.
Materials and methods
Study design, settings, participants
Following institutional review board approval at both institutions, all cases of type II EC
treated at Beijing Obstetrics and Gynecology Hospital in Beijing, China and the University of
North Carolina Women’s Hospital in Chapel Hill, North Carolina, USA from June 2001 to
June 2010 were identified. Inclusion criteria were a confirmed pathologic diagnosis of type II
EC and available peritoneal cytologic results. Patients who did not undergo peritoneal cytology
were excluded from this study. Additional exclusion criteria included (1) endometrioid histol-
ogy or non-epithelial histology, (2) synchronous malignancy, and (3) evidence of lymphatic or
distant metastasis at the time of diagnosis, and (4) diagnosis via method other than D&C or
HSC. Overall, 165 histologically confirmed cases of type II EC were identified. Thirteen cases
were excluded due to lack of peritoneal cytology results, 5 cases for preoperative evidence of
lymphatic or distant metastasis and 4 cases based on not undergoing HSC or D&C for diagno-
sis. Overall, 140 cases met the criteria for evaluation and were included in this retrospective
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cohort analysis. STROBE guidelines were followed in the design and reporting of this study
[18].
Data sources and variables
Demographic and clinical information were abstracted for each patient using medical records.
For study purposes all patients were staged using the 2009 International Federation of Gyne-
cology and Obstetrics (FIGO) staging system for EC [19]. The following demographic and
clinical data were obtained: age, preoperative diagnosis, diagnostic procedure performed
(D&C or HSC), FIGO 2009 stage, postoperative histologic type, depth of myometrial invasion,
cervical stromal involvement, lymph vascular space invasion, adnexal and lymph nodes metas-
tasis, adjuvant therapy received, disease recurrence date and location, and date and cause of
death or last follow up.
The exposure of interest was HSC. Referral records and operative reports were obtained to
determine if a patient underwent HSC with biopsy/D&C (n = 54) or D&C alone (n = 86) for
diagnosis. Patients who underwent only office endometrial biopsy were excluded from this
analysis. The D&C and HSC could be performed at either of the two study institutions or at an
outside institution prior to referral. D&C was performed using traditional curettage biopsy.
HSC was performed with or without anesthesia as per institutional practice. The uterine cavity
was then distended with either 0.9% sodium saline or 5% glucose solution to a pressure range
of 80–110mmHg. Following HSC, either traditional curettage or hysteroscopic-directed biopsy
was performed. In the HSC group, 51 patients (94%) performed HSC followed by curettage,
and 3 patients (6%) underwent HSC with directed biopsy.
Following the diagnostic procedure, surgical staging was performed in all patients. Almost
all patients had pelvic ultrasonography or pelvic and abdominal CT or MRI examination
before surgery, except patients diagnosed after surgery. Presumed early stage patients under-
went planned complete surgical staging with total hysterectomy and bilateral salpingo-oopho-
rectomy with peritoneal washings in all patients. Complete pelvic and para-aortic lymph node
dissections were performed as feasible. Both open and minimally invasive surgeries were
included. All patients with evidence of advanced stage at the time of surgery underwent a
tumor cytoreductive surgery, however, patients with evidence of advanced stage disease at the
time of diagnosis were excluded from this study. Ascites or peritoneal washings were taken in
all patients included in this study. Experienced gynecologic cytopathologists and gynecologic
pathologists at the corresponding institution reviewed all cytologic and pathologic samples.
Adjuvant treatment with either radiotherapy and/or adjuvant chemotherapy were adminis-
tered per institutional practices for incomplete tumor resections, lymph node metastases, deep
myometrial invasion, adnexal metastases, and extensive lymphovascular space invasion. Adju-
vant radiotherapy included the use of external beam pelvic radiation (4000~ 4500cGy) and
vaginal brachytherapy. When adjuvant chemotherapy was administered the regimens used
included platinum/paclitaxel (carboplatin AUC 4–6 or cisplatin 60mg/m2, d1; paclitaxel 175
mg/m2, d1, q 21 days) and PAC (carboplatin AUC 4–6 or cisplatin 60mg/m2, d1; epirubicin
50mg/m2, d1; cyclophosphamide 500mg/m2, q 21 days). The courses of chemotherapy ranged
from 2 to 6.
Patients were followed from the time of surgery until June 2015 for the purposes of this
study. Patients were followed up at 3-month intervals for the first 2 years, at 6-month intervals
for the next 3 years and, thereafter, once a year from the fifth year on. The primary outcome of
interest was disease-specific survival (DSS). DSS was defined as the interval from the date of
surgery to death from disease. Patients were censored at the time of their last follow up. Sec-
ondary outcomes included progression-free survival (PFS), stage at diagnosis, presence of
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positive peritoneal cytology at the time of staging surgery, and recurrence patterns. For patients
with stage III and IV disease, the beginning of the disease free interval was defined as no residual
tumor on imaging, absence of clinical symptoms, and normalization of tumor markers if ele-
vated prior to therapy. PFS was defined as the time interval from surgery to the first evidence of
recurrence (using clinical exam findings or radiologic findings) or death from any cause.
Statistical methods
Statistical analyses were performed using SPSS (version 17.0) statistical software. Continuous
variables were compared using Student’s t test. Categorical variables were compared using x2
test. PFS and DSS were estimated with the Kaplan-Meier method and survival curves were
compared by log-rank test. A p value of less than 0.05 was considered statistically significant.
Results
Participants’ demographic and clinical characteristics
The average age at diagnosis was 61.2±9.5 years. One hundred and twenty-three patients
(88%) were postmenopausal. Sixty patients (43%) had serous adenocarcinoma, 37 (26%) had
clear cell carcinoma, 31 (22%) had carcinosarcoma and 12(9%) had mixed histology. All
patients underwent total hysterectomy and bilateral salpingo-oophorectomy with 132 (94%)
patients undergoing pelvic lymph node dissection and 91(65%) also undergoing aortic lymph
node dissection. Adjuvant therapy was administered to 111(79%) patients. Of those receiving
adjuvant therapy, 15(11%) received adjuvant radiation only (XRT), 34(24%) received adjuvant
chemotherapy (CT) only, and 62 (44%) received both XRT and CT. Overall, 76 (54%) were
stage I, 23(16%) were stage II, 33 (24%) were stage III, and 8(6%) were stage IV.
Comparing the HSC group (n = 54) to the D&C only group (n = 86), there was no signifi-
cant difference in age at diagnosis (61.4 vs. 61.1 years, p = 0.86), histology (46% serous vs. 41%
serous, p = 0.65), stage at diagnosis (26% stage III/IV vs. 31%, p = 0.81), or receipt of adjuvant
treatment (p = 0.22). There was also no difference in pathologic characteristics between groups
with 39% of the HSC group and 38% in the D&C group had outer half myometrial invasion
(p = 0.95). Approximately one-third of each group had lymphovascular space invasion. Fifteen
percent of patients in the HSC group had lymph node metastasis versus 23% in the D&C
group (p = 0.22). These findings are summarized in Table 1.
Peritoneal cytology
Positive pelvic washings were seen on cytology in 26 patients (25%) overall. A higher incidence
of positive washings was noted in patients undergoing HSC compared to D&C (n = 16, 30%
versus n = 10, 12%, p = 0.008). Fourteen patients with stage I and II had positive peritoneal
cytology, with 11/40 (28%) of patients in HSC group and 3/59(5%) patients in D&C group
(p = 0.002). While for stage III and IV patients, positive peritoneal cytology were found in 5/14
(36%) of patients in HSC group and 7/27(26%) in D&C group, the rate had no significance
(p = 0.51).
Survival and recurrence patterns
The median overall follow-up time for this cohort was 66 months (range 6–140 months). For
the two diagnostic subgroups, follow-up period ranged (median) from 8 to 140 (72) and 6 to
133 (61) months for D&C and HSC, respectively. At the time of analysis, 71 patients were alive
without disease, 43 patients were dead of EC, and 9 cases were dead of other causes. Survival
data was missing on 15 patients and these patients were censored at the time of last follow up.
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The DSS and PFS curves are shown in Fig 1 and Fig 2. There were no significant differences in
DSS and PFS between D&C and HSC group for all stage patients. The median DSS was 53
months for HSC and 63.5 months for D&C (p = 0.34). The median PFS was 47.5 months for
HSC and 60 months for D&C (p = 0.66).
For stage I and II patients, 18/99 (18%) died of EC, The median DSS was 60 months for
HSC and 71 months for D&C (p = 0.82). Fig 3 shows the DSS curves. The median PFS was 60
months for HSC and 68 months for D&C (p = 0.99). PFS is displayed in Fig 4.
Overall 46 patients (33%) experienced a disease recurrence. There were 18/54 (33%)
patients with recurrence in the HSC group compared to 28/86 (32%) in the D&C group
(p = 0.92). For stage I and II patients, 7/40 (18%) patients had a recurrence in the HSC group
and 12/59 (20%) patients in the D&C group (p = 0.72). While for stage III and IV patients,
recurrence developed in 11/14 (79%) patients in HSC group and 16/27 (60%) patients in D&C
group (p = 0.22). Among the patients who recurred, 28 (61%) developed local recurrence, 25
(54%) experienced distant metastasis, and 7 (15%) had both local and distant recurrence. The
most common locations of distant metastasis were lung (11/25, 44%), but other sites included
brain (4/25,16%), lymph nodes (9/25, 36%), and liver (1/25, 4%). There was no difference in
site of recurrence between the two groups, both in early stage and advanced stage (Table 2).
Discussion
In the present study, we investigated whether HSC to aid in the diagnosis of EC lead to a worse
prognosis in women with type II tumors. We found that HSC is associated with an increased
Table 1. Comparison of clinical and pathological characteristics.
Hysteroscopy D&C P value
n = 54 n = 86
Age (SD, years) 61.4 (9.3) 61.1 (9.7) 0.86
Histology 0.65
Serous 25 (46) 35 (41)
Clear cell 11 (20) 26 (30)
Carcinosarcoma 13 (24) 18 (21)
Other/Mixed 5 (9) 7 (8)
Stage 0.81
I 30 (56) 46 (53)
II 10 (19) 13 (15)
III 12 (22) 21 (24)
IV 2 (4) 6 (7)
Treatment* 0.22
S 7 (13) 22 (26)
S+XRT 6 (11) 9 (10)
S+CT 17 (31) 17 (20)
S+XRT+CT 24(44) 38 (44)
Outer half myometrial invasion 21 (39) 33 (38) 0.95
Lymph node metastasis 8 (15) 20 (23) 0.22
Lymphovascular space invasion 18 (33) 26 (30) 0.70
Adnexal metastasis 5 (9) 14 (16) 0.24
Continuous variables are reported as mean (+/- standard deviation); categorical variables are reported as n(%).
* S = surgery, XRT = radiation, CT = chemotherapy.
https://doi.org/10.1371/journal.pone.0174226.t001
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rate of positive peritoneal cytology in patients with type II EC (30 versus 12%, p = 0.008),
theoretically due to expulsion of malignant cells through the fallopian tubes after uterine
distension. Despite this difference in peritoneal cytology, we were unable to detect a dif-
ference in prognosis with a median DSS of 53 versus 63.5 months in the HSC and D&C arms,
respectively.
Regarding positive cytology, our study results are similar to prior studies that evaluated the
effects of HSC on positive cytology in predominantly type I EC [20–25]. However, given the
more aggressive nature of type II EC, this study adds to the literature by specifically evaluating
the effect of HSC on type II tumors. Previously reported rates of positive cytology at the time
of endometrial cancer staging have varied widely. Takac et al [20] reported a 12.5% rate of pos-
itive peritoneal cytology after HSC compared with 1.6% rate without HSC in 146 patients with
EC. This cohort included predominantly endometrioid adenocarcinomas (86%), suggesting
that diagnostic HSC increases the risk of positive peritoneal cytology. While some authors
have not found evidence to support an increased rate of positive peritoneal cytology after HSC,
two large meta-analyses have concluded that the rate of positive peritoneal cytology after HSC
is significantly higher than after D&C alone[14,16]. In addition to focusing on type II EC, our
study is unique in that the rate of positive cytology was higher than previous reported in the lit-
erature[12,21,22,24,26]. We hypothesize that the increased rate of positive cytology was likely
due to the aggressive nature of type II EC with increased necrosis and cellular sloughing, as
prior series have included relatively small numbers of type II tumors. Further, in order to
decrease potential bias caused by advanced stage, the positive cytology rate in stage I and II
tumors was compared between two groups with a significant difference seen.
While the finding of positive cytology is intriguing, the real question is whether this results
in impaired clinical outcomes and worse survival. At present, studies on the effect of HSC on
prognosis are predominately retrospective and focused on type I tumors. There has been no
association between HSC and poor prognosis in studies to date [15,25,27–29]. One of the
Fig 1. Disease-specific survival in patients with type II endometrial cancer diagnosed with
hysteroscopy (HSC) versus D&C.
https://doi.org/10.1371/journal.pone.0174226.g001
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largest studies by Soucie et al evaluated 1972 patients with type I EC and found no association
between advanced stage or mortality in patients undergoing HSC [15]. These authors con-
cluded that HSC is a safe diagnostic tool for identifying EC. However, the prognostic effect of
HSC has not been well described in the literature for type II tumors.
Fig 2. Progression-free survival in patients with type II endometrial cancer diagnosed with
hysteroscopy (HSC) versus D&C.
https://doi.org/10.1371/journal.pone.0174226.g002
Fig 3. Disease-specific survival curves in patients with type II endometrial cancer for stage I and II
diagnosed by HSC and D&C.
https://doi.org/10.1371/journal.pone.0174226.g003
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There is conflicting evidence regarding the prognostic significance of positive peritoneal
cytology among patients with early stage EC, and the International Federation of Gynecology
and Obstetrics (FIGO) staging criteria has eliminated cytology from surgical staging[30].
However, positive peritoneal cytology can add prognostic value, particularly in type II EC.
Han et al found that positive peritoneal cytology is an independent prognostic factor for
patients with non-endometrioid endometrial cancer [31]. Patients with positive peritoneal
cytology were more frequently diagnosed with high-risk factors such as clear cell/ serous carci-
noma and carcinosarcoma, and are at significant risk of lymph nodal metastasis and adverse
prognosis[32]. In our cohort of type II tumors, there was no significant difference in survival
with patients in the HSC group and D&C group. Tumor metastasis occurs via multiple
Fig 4. Progression free survival curves in patients with type II endometrial cancer for stage I and II
diagnosed by HSC and D&C.
https://doi.org/10.1371/journal.pone.0174226.g004
Table 2. Recurrence patterns between groups.
Stage I and II Stage III and IV
n = 99 n = 41
Hysteroscopy D&C P value Hysteroscopy D&C P value
n = 40 n = 59 n = 14 n = 27
Local regional recurrence 4(10) 9(15) 0.448 6(43) 9(33) 0.548
Vaginal cuff 2(50) 5(56) 2(33) 3(33)
Pelvis 2(50) 4(44) 4(67) 6(67)
Distant recurrence 4(10) 6(10) 1.000 7(50) 8(30) 0.199
Lung 2(50) 3(50) 2(29) 4(50)
Brain 1(25) 0(0) 2(29) 1(12)
Lymph nodes 1(25) 2(33) 3(43) 3(38)
Liver 0(0) 1(17) 0(0) 0(0)
Local and distant recurrence 1(3) 3(5) 0.904 2(14) 1(4) 0.217
Categorical variables are reported as n (%).
https://doi.org/10.1371/journal.pone.0174226.t002
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potential mechanisms [33], including peritoneal dissemination, lymphatic spread and vascular
dissemination. By limiting our analysis to presumed early stage patients and eliminating
patients with known lymphatic and vascular spread on imaging we are able to focus on the
role of peritoneal dissemination which could be increased following HSC. For stage I and II
patients, we did see a clinically meaningful but statistically insignificant difference in survival
with patients in the HSC group with a median DSS of 60 months compared to 71 months in
the D&C group(p = 0.82).
One hypothesis to address the difference in rate of positive cytology but lack of survival dif-
ference seen in our study, as well as prior studies in type I tumors, is the inability of EC cells to
survive when floating in the peritoneal cavity. Hirai et al [34] investigated the malignant poten-
tial of positive peritoneal cytology in EC and suggested that cancer cells found in the peritoneal
cavity usually disappear within a short time. Perhaps, free floating tumor cells in the peritoneal
cavity lack the microenvironment and nutrients needed for tumor growth resulting in loss of
tumor activity. Additionally, we noted a high rate of adjuvant therapy and receipt of adjuvant
radiotherapy and chemotherapy may affect the bioactivity of malignant cells in the peritoneal
cavity before the invasion and metastasis can occur. However, other studies have shown that
tumor cells disseminated at time of hysterectomy or HSC are biologically viable and have the
ability to replicate in vitro [35]. In the absence of adjuvant treatment, peritoneal cell dissemina-
tion may result in adverse outcomes. Further supporting the importance of tubal dissemina-
tion of endometrial cancer are recent studies reporting that tubal ligation is associated with
decreased stage of EC, reduced peritoneal metastasis, and improved mortality, particularly in
serous and other high-risk histologic types[36–38].
Additionally, the current study is likely underpowered to detect a survival difference. Thus,
while our study adds to the literature as the first to specifically evaluate the effect of HSC on
type II EC, several limitations must be acknowledged. The main limitation is that a relatively
small number of patients were included, given the rarity of type II EC. A post hoc power calcu-
lation suggests over 500 patients are needed to detect a survival difference. Another important
limitation is the retrospective design of this study. There is a potential for selection bias with
differing populations undergoing D&C versus HSC. Further, postoperative treatment was
given without well-defined protocols for type II EC and may reflect institutional biases or prac-
tice patterns. Additionally, recent studies on molecular and pathological features, show that
nearly 25% of endometrial cancers do not fall neatly into the traditional two tier system of
endometrial cancer subtypes with significant molecular heterogeneity[39–41]. In this study we
used the traditional Bokhman classification of EC (type I and II) while recognizing there may
be a role for including grade 3 endometrioid carcinomas with traditional type II ECs based on
clinical features and survival outcomes[33]. Further, other unmeasured risk factors or charac-
teristics of the tumors may have influenced peritoneal dissemination and pelvic recurrence
aside from HSC. Despite these limitations, we feel that our study provides more information
on the effect of HSC on peritoneal cytology and outcomes in type II EC.
Our data for type II EC indicate that HSC significantly increases the rate of positive perito-
neal cytology at the time of surgical staging in patients with type II EC. While we were unable
to demonstrate a statistical difference in prognosis, we did note an interesting trend toward
shorter median survival in the HSC group when evaluating patients with all stages of disease.
We found no difference in recurrence rate or survival when limiting our analysis to stage I and
II patients. Future studies are needed to evaluate the impact of HSC on prognosis in patients
with type II EC and will likely require large collaborations to obtain the sample size needed for
this relatively rare disease. Providers should understand a potential risk of peritoneal dissemi-
nation of tumor cells following HSC, particularly in type II tumors, however the effect on
prognosis remains unclear.
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